Overview
- Editors:
-
-
Martin Welschof
-
Axaron Bioscience AG, Heidelberg, Germany
-
Jürgen Krauss
-
National Institutes of Health, National Cancer Institute, Frederick
Access this book
Other ways to access
Table of contents (28 protocols)
-
Antibody Fragments with Additional Properties
-
- Cyril J. Cohen, Galit Denkberg, Dina Segal, Yoram Reiter
Pages 269-282
-
- Dianne L. Newton, Junichiro Futami, Dale Ruby, Susanna M. Rybak
Pages 283-304
-
- Michaela Arndt, Jürgen Krauss
Pages 305-321
-
-
- Barbara E. Power, Alexander A. Kortt, Peter J. Hudson
Pages 335-350
-
- Paul J. Yazaki, Anna M. Wu
Pages 351-364
-
- Andreas Hombach, Claudia Heuser, Hinrich Abken
Pages 365-381
-
- Ole H. Brekke, John E. Thommesen
Pages 383-391
-
- Christian Kleist, Daniéle Arnold-Schild, Martin Welschof, Martina Finger, Gerhard Opelz, Hans-Georg Rammensee et al.
Pages 393-420
-
- Roland E. Kontermann, Tina Korn, Valérie Jérôme
Pages 421-433
-
Large Scale Production of Recombinant Antibodies for Clinical Application
-
Front Matter
Pages 435-435
-
-
- Itai Benhar, Yevgeny Berdichevsky
Pages 443-454
-
- Carmen Vaquero-Martin, Rainer Fischer
Pages 455-466
-
Back Matter
Pages 467-481
About this book
Since the advent of hybridoma technology more than two decades ago, numerous antibodies have entered the clinical setting as potent therapeutic agents. Their repeated application in humans, however, is limited by the development of human antimouse antibodies (HAMA) in the recipient, leading to allergic re- tions against the foreign murine protein and rapid neutralization. To circumvent these limitations many new antibodies have recently been tailored through recombinant antibody technology. The initial clinical data show encouraging results, thus demonstrating the potential of these new therapeutic agents. The purpose of Recombinant Antibodies for Cancer Therapy is to present a collection of detailed protocols in recombinant antibody technology. It is pri- rily addressed to scientists working on recombinant antibodies as well as cli- cians involved with antibody-based therapies. As with other volumes of this series, we placed the main focus on providing detailed protocols describing procedures step-by-step. Moreover, each protocol supplies a troubleshooting guide containing detailed information on possible problems and hints for pot- tial solutions. Antibody technology is a subject of constant and rapid change. This volume, therefore, does not attempt to cover all possible current experimental approaches in the field. Rather, we present carefully selected protocols, written by competent authors who have successfully verified the particular method described. Given our own professional backgrounds and interest in oncology, we chose to conc- trate chiefly on therapeutic agents for cancer patients.
Reviews
"...the book is well written and the experimental protocols that were included are described in great detail...this book is a valuable resource both for persons new to this field to get an overview of current activities and for those already in the field to look up specific areas that are covered." -Clinical Immunology
"Overall the book is a helpful resource, especially for molecular biologists involved in generating antibody fragments, collecting up to date protocols in one convenient volume." - Pharmaceutical Research
Editors and Affiliations
-
Axaron Bioscience AG, Heidelberg, Germany
Martin Welschof
-
National Institutes of Health, National Cancer Institute, Frederick
Jürgen Krauss
